TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ).
Venus Medtech (Hangzhou) Inc. has announced an extraordinary general meeting to be held on November 28, 2025, to approve a Disposal Agreement with Hangzhou Binjiang Urban Construction Development Co., Ltd. This agreement involves the disposal of construction in progress and associated land use rights, potentially impacting the company’s operational focus and asset management strategy.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a joint stock company incorporated in the People’s Republic of China. It operates within the medical technology industry, focusing on developing and providing innovative medical devices.
Average Trading Volume: 3,650,447
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.06B
For detailed information about 2500 stock, go to TipRanks’ Stock Analysis page.